This study found that acute myeloid leukemia (AML) cells driven by the fusion oncogenes AML1-ETO and PML-RARα have increased DNA damage and are more sensitive to PARP inhibitors compared to AML cells driven by MLL-AF9. Sensitivity to PARP inhibitors was correlated with lower expression of DNA damage response genes. The study also found that modulating the activity of the oncogene HOXA9, which is highly expressed in MLL-AF9 AML, could render those cells sensitive to PARP inhibitors by reducing DNA repair capacity. Combining PARP inhibitors with agents that target HOXA9 may be a promising new therapeutic strategy for AML.
Annals of Mutagenesis is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Mutagenesis.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Mutagenesis. Annals of Mutagenesis accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of mutagenesis.
Annals of Mutagenesis strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Annals of Mutagenesis is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Mutagenesis.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Mutagenesis. Annals of Mutagenesis accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of mutagenesis.
Annals of Mutagenesis strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Purpose: An inherited mutation in KRAS (LCS6-variant or rs61764370) results in altered control of the KRAS oncogene. We studied this biomarker’s correlation to anti-EGFR monoclonal antibody (mAb) therapy
response in patients with metastatic colorectal cancer.
Experimental Design: LCS6-variant and KRAS/BRAF mutational status was determined in 512 patients
with metastatic colorectal cancer treated with salvage anti-EGFR mAb therapy, and findings correlated with
outcome. Reporters were tested in colon cancer cell lines to evaluate the differential response of the LCS6-
variant allele to therapy exposure.
Results: In this study, 21.2% (109 of 512) of patients with metastatic colorectal cancer had the LCS6-
variant (TG/GG), which was found twice as frequently in the BRAF-mutated versus the wild-type (WT) group
(P = 0.03). LCS6-variant patients had significantly longer progression- free survival (PFS) with anti-EGFR
mAb monotherapy treatment in the whole cohort (16.85 vs. 7.85 weeks; P = 0.019) and in the double WT
(KRAS and BRAF) patient population (18 vs. 10.4 weeks; P = 0.039). Combination therapy (mAbs plus
chemotherapy) led to improved PFS and overall survival (OS) for nonvariant patients, and brought their
outcome to levels comparable with LCS6-variant patients receiving anti-EGFR mAb monotherapy. Combination
therapy did not lead to improved PFS or OS for LCS6-variant patients. Cell line studies confirmed a
unique response of the LCS6-variant allele to both anti-EGFR mAb monotherapy and chemotherapy.
Conclusions: LCS6-variant patients with metastatic colorectal cancer have an excellent response to anti-EGFR
mAb monotherapy, without any benefit from the addition of chemotherapy. These findings further confirm
the importance of thismutation as a biomarker of anti-EGFR mAb response in patients with metastatic colorectal cancer, and warrant further prospective confirmation.
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...UCLA
Germ-line variants in the 3′ untranslated region (3′UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3′UTR of the KRAS oncogene, referred to as the KRAS-variant, is associated with both cancer risk and altered tumor biology. Here we test the hypothesis that the KRAS-variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS-variant positive EOC patients. As this variant appears to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival.
EOC patients with complete clinical data were genotyped for the KRAS-variant and analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125), and platinum resistance (n=306). Outcome was separately analyzed for women with known BRCA mutations (n=79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were employed to confirm altered sensitivity to chemotherapy with the KRAS-variant. The KRAS- variant was directly targeted through siRNA/miRNA oligonucleotides in cell lines and survival was measured.
Post-menopausal EOC patients with the KRAS-variant were significantly more likely to die of ovarian cancer by multivariate analysis (HR=1.67, 95% CI=1.09–2.57, p=0.019, n=279). Possibly explaining this finding, EOC patients with the KRAS-variant were significantly more likely to be platinum resistant (OR=3.18, CI=1.31–7.72, p=0.0106, n=291). Additionally, direct targeting of the KRAS-variant led to a significant reduction in EOC cell growth and survival in vitro.
These findings confirm the importance of the KRAS-variant in EOC, and indicate that the KRAS- variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this work supports the hypothesis that these tumors have continued dependence on such 3′UTR lesions, and that direct targeting may be a viable future treatment approach.
tratamientos para el mieloma multiple WHAT IS MM? Multiple myeloma (MM) is the second most common cancer of the blood formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Despite recent advances, remains incurable in the vast majority of patients.
In the United States, there will be an estimated 24,050 new cases of MM in 2014 and >60,000 individuals living with the disease. Worldwide, ~86,000 patients are diagnosed each year with myeloma, while ~63,000 patients die every year from disease-related complications.
WHERE DOES EVERYTHING START? Everything start in plasma cells which are mainly found in bone marrow. Bone marrow is the soft tissue inside some hollow bones.
WHAT HAPPENS? When plasma cells become cancerous and grow out of control, they can produce a tumor called a plasmacytoma. These tumors generally develop in a bone, if someone has more than one plasmacytoma, they have multiple myeloma. (Isolated (or solitary) plasmacytoma si es uno solo).
The growth of this tumor, weakens the bones and also makes it harder the formation of healthy blood cells and platelets. According to this…
WHAT CAN WE EXPECT TO FOUND? As we know, the bone marrow produces blood cells, if a tumor in the bone occurs, we see:
• decreases the number of red blood cells: which leads to have an anemia
• Decreases the number of white blood cells: which favors infections cause, plasma cells make the antibodies (also called immunoglobulins) that help the body attack and kill germs. (leucopenia)
• diminishes the number of platelets: that can be evidenced with unusual bleeding (trombocitopenia)
We can also found b
Cancer Epigenetics: Concepts, Challenges and PromisesMrinmoy Pal
The presentation highlights how recent investigations have shown extensive reprogramming of almost every component of the epigenetic machinery in cancer leading to the emergence of the promising field of epigenetic therapy.
Epigenetic silencing of MGMT (O6-methylguanine DNA methyltransferase) gene in...arman170701
O6–methylgunine-DNA methyltransferace (MGMT) is a DNA binding protein that is involved in repairing mutations.
MGMT gene - a tumor suppressor gene that codes MGMT (O6-methylguanine DNA methyltransferase) protein.
The MGMT protein removes mutagenic methyl groups from guanines through the methyltransferase activity.
Spartanburg Methodist College (SMC) is a private,
two-year liberal arts college affiliated with the United
Methodist Church. Originally founded in 1911 as the
Textile Industrial Institute, Spartanburg Methodist now
offers six associate degree programs and is accredited by
the Commission on Colleges of the Southern Association
of Colleges and Schools. Eighty-six percent of graduates
continue their education at other universities and colleges.
More at: www.hobsons.com
Purpose: An inherited mutation in KRAS (LCS6-variant or rs61764370) results in altered control of the KRAS oncogene. We studied this biomarker’s correlation to anti-EGFR monoclonal antibody (mAb) therapy
response in patients with metastatic colorectal cancer.
Experimental Design: LCS6-variant and KRAS/BRAF mutational status was determined in 512 patients
with metastatic colorectal cancer treated with salvage anti-EGFR mAb therapy, and findings correlated with
outcome. Reporters were tested in colon cancer cell lines to evaluate the differential response of the LCS6-
variant allele to therapy exposure.
Results: In this study, 21.2% (109 of 512) of patients with metastatic colorectal cancer had the LCS6-
variant (TG/GG), which was found twice as frequently in the BRAF-mutated versus the wild-type (WT) group
(P = 0.03). LCS6-variant patients had significantly longer progression- free survival (PFS) with anti-EGFR
mAb monotherapy treatment in the whole cohort (16.85 vs. 7.85 weeks; P = 0.019) and in the double WT
(KRAS and BRAF) patient population (18 vs. 10.4 weeks; P = 0.039). Combination therapy (mAbs plus
chemotherapy) led to improved PFS and overall survival (OS) for nonvariant patients, and brought their
outcome to levels comparable with LCS6-variant patients receiving anti-EGFR mAb monotherapy. Combination
therapy did not lead to improved PFS or OS for LCS6-variant patients. Cell line studies confirmed a
unique response of the LCS6-variant allele to both anti-EGFR mAb monotherapy and chemotherapy.
Conclusions: LCS6-variant patients with metastatic colorectal cancer have an excellent response to anti-EGFR
mAb monotherapy, without any benefit from the addition of chemotherapy. These findings further confirm
the importance of thismutation as a biomarker of anti-EGFR mAb response in patients with metastatic colorectal cancer, and warrant further prospective confirmation.
A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistan...UCLA
Germ-line variants in the 3′ untranslated region (3′UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3′UTR of the KRAS oncogene, referred to as the KRAS-variant, is associated with both cancer risk and altered tumor biology. Here we test the hypothesis that the KRAS-variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS-variant positive EOC patients. As this variant appears to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival.
EOC patients with complete clinical data were genotyped for the KRAS-variant and analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125), and platinum resistance (n=306). Outcome was separately analyzed for women with known BRCA mutations (n=79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were employed to confirm altered sensitivity to chemotherapy with the KRAS-variant. The KRAS- variant was directly targeted through siRNA/miRNA oligonucleotides in cell lines and survival was measured.
Post-menopausal EOC patients with the KRAS-variant were significantly more likely to die of ovarian cancer by multivariate analysis (HR=1.67, 95% CI=1.09–2.57, p=0.019, n=279). Possibly explaining this finding, EOC patients with the KRAS-variant were significantly more likely to be platinum resistant (OR=3.18, CI=1.31–7.72, p=0.0106, n=291). Additionally, direct targeting of the KRAS-variant led to a significant reduction in EOC cell growth and survival in vitro.
These findings confirm the importance of the KRAS-variant in EOC, and indicate that the KRAS- variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this work supports the hypothesis that these tumors have continued dependence on such 3′UTR lesions, and that direct targeting may be a viable future treatment approach.
tratamientos para el mieloma multiple WHAT IS MM? Multiple myeloma (MM) is the second most common cancer of the blood formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Despite recent advances, remains incurable in the vast majority of patients.
In the United States, there will be an estimated 24,050 new cases of MM in 2014 and >60,000 individuals living with the disease. Worldwide, ~86,000 patients are diagnosed each year with myeloma, while ~63,000 patients die every year from disease-related complications.
WHERE DOES EVERYTHING START? Everything start in plasma cells which are mainly found in bone marrow. Bone marrow is the soft tissue inside some hollow bones.
WHAT HAPPENS? When plasma cells become cancerous and grow out of control, they can produce a tumor called a plasmacytoma. These tumors generally develop in a bone, if someone has more than one plasmacytoma, they have multiple myeloma. (Isolated (or solitary) plasmacytoma si es uno solo).
The growth of this tumor, weakens the bones and also makes it harder the formation of healthy blood cells and platelets. According to this…
WHAT CAN WE EXPECT TO FOUND? As we know, the bone marrow produces blood cells, if a tumor in the bone occurs, we see:
• decreases the number of red blood cells: which leads to have an anemia
• Decreases the number of white blood cells: which favors infections cause, plasma cells make the antibodies (also called immunoglobulins) that help the body attack and kill germs. (leucopenia)
• diminishes the number of platelets: that can be evidenced with unusual bleeding (trombocitopenia)
We can also found b
Cancer Epigenetics: Concepts, Challenges and PromisesMrinmoy Pal
The presentation highlights how recent investigations have shown extensive reprogramming of almost every component of the epigenetic machinery in cancer leading to the emergence of the promising field of epigenetic therapy.
Epigenetic silencing of MGMT (O6-methylguanine DNA methyltransferase) gene in...arman170701
O6–methylgunine-DNA methyltransferace (MGMT) is a DNA binding protein that is involved in repairing mutations.
MGMT gene - a tumor suppressor gene that codes MGMT (O6-methylguanine DNA methyltransferase) protein.
The MGMT protein removes mutagenic methyl groups from guanines through the methyltransferase activity.
Spartanburg Methodist College (SMC) is a private,
two-year liberal arts college affiliated with the United
Methodist Church. Originally founded in 1911 as the
Textile Industrial Institute, Spartanburg Methodist now
offers six associate degree programs and is accredited by
the Commission on Colleges of the Southern Association
of Colleges and Schools. Eighty-six percent of graduates
continue their education at other universities and colleges.
More at: www.hobsons.com
Centenary College of Louisiana is a private,
four-year arts and sciences college affiliated with
the United Methodist Church. Founded in 1825,
it is the oldest chartered liberal arts college west of
the Mississippi River. Centenary College believes in
encouraging their students to become leaders, but
the school’s technology processes weren’t leading
their own admissions team to success.
More at: www.hobsons.com
Hope College is a private, four-year liberal arts school
historically associated with the Reformed Church in
America. With an enrollment of over 3,000 students,
Hope offers 91 majors and minors and is the only liberal
arts college in the country with national accreditations
in art, dance, music, and theater
More at: www.hobsons.com
Annenberg School for Communication Case StudyHobsons
The Annenberg School for Communication at the University
of Pennsylvania serves to further understanding of the role of
communications in public life. However, their recruitment
outreach had been relying on traditional communications,
graduate fairs, and word-of-mouth to attract students.
More at: www.hobsons.com
Saint Joseph’s University (SJU) contracted with Hobsons out of a
need to increase the school’s number of student connections and
applicants. Additionally, recruitment professionals at the university
wanted to reach a more diverse pool of students interested in
applying to SJU. For years they had recruited regionally, but now
they were looking to attract students from more diverse geographic,
racial, and ethnic backgrounds.
More at: www.hobsons.com
Portrait d'ensemble de la science ouverte. Colloque de Port au PrinceFlorence Piron
Conférence prononcée lors du colloque « La science ouverte et le libre accès aux ressources scientifiques dans les universités haïtiennes : état des lieux et propositions »
Inhibition of glutathione by buthionine sulfoximine enhanced the anti-cancer ...Ashujit
Multiple myeloma (MM) is an incurable blood cancer. Melphalan is an alkylating agent given prior to stem cell transplantation to MM patients. Increased glutathione confers resistance to melphalan. This study investigate the effect of inhibition of glutathione by BSO in preclinical models of MM. Pretreatment with BSO enhanced the anti-cancer effect of melphalan in cell lines and animal models. BSO and melphalan combination was well tolerated by animals and enhanced the survival as compared to controls, BSO and melphalan alone. BSO enhanced depth and duration of responses induced by melphalan. In the combination group, majority of treated animals achieved complete response (CR) and more than 20% had maintained CR. Also, the survival of animals was doubled after combination treatment as compared to BSO or melphalan alone. Mechanistic investigation demonstrated that BSO enhanced melphalan induced DNA damage, caspase cleavage and apoptosis. The combination also achieved multi-logs of cells kills in nine human multiple myeloma cell lines and primary MM cells isolated from blood and bone marrows. Interestingly, the effect of BSO and melphalan combination was abolished when cells were treated with N-acetyl cysteine and sodium thiosulfate but not with vitamin C and vitamin E. This observation suggests that effect of BSO is primarily driven by its ability to deplete glutathione and therefore preventing melphalan detoxification. Together, this study provides framework for testing the combination in a Phase I trial.
Proteogenomic analysis of human colon cancer reveals new therapeutic opportun...Gul Muneer
We performed the first proteogenomic study on a prospectively collected colon cancer cohort. Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens. Proteogenomic integration not only prioritized genomically inferred targets, such as copy-number drivers and mutation-derived neoantigens, but also yielded novel findings. Phosphoproteomics data associated Rb phosphorylation with increased proliferation and decreased apoptosis in colon cancer, which explains why this classical tumor suppressor is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon cancer. Proteomics identified an association between decreased CD8 T cell infiltration and increased glycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade. Proteogenomics presents new avenues for biological discoveries and therapeutic development.
P53 Tumor Suppressor Gene: Understanding P53 Based Dietary Anti Cancer Thera...Sheldon Stein
The P53 tumor suppressor gene which has been dubbed both the “Guardian of the Genome” (Lane 1992) and Science “Molecule of the Year”, is directly involved in the initiation of apoptosis and programmed cell death, to prevent an accumulation of abnormal cells. However apoptosis evasion is a characteristic feature of human cancers that promote tumor formation and progression (1). Presently, P53 is known to play a key role in practically all types of human cancers, and the mutation or loss of P53 gene function, can be identified in more than 50% of all human cancer cases worldwide.
This paper was uploaded on behalf of Professor Serge Jurasunas of Lisbon Portugal, www.sergejurasunas.com
The paper goes on to explain the role of the P53 gene and its relationship to Cancer and Apoptosis. It then elaborates on the importance of dietary agents can have a beneficial impact in cancer treatment, and provides a number of case studies. He addresses the importance of the P53 gene and DNA repair, as well as his use of Molecular Markers testing.
Professor Jurasunas believes:
We urgently need to put into clinical practice what we have discovered and learned. Targeting P53 and other genes remain one of the greatest challenges in the treatment of cancer. We have been working now for over 8 years with molecular markers as a diagnostic, prognosis, and follow up to treatment, selected the appropriate bioactive dietary compounds or anticancer agents, exceeding 1000 cases, blood tests, and successes. This may be an incentive for more doctors to venture into this new direction in order to achieve more beneficial results with their patient treatment, especially in cases where we can verify the ones who would be refractory to chemotherapy and have a poor response. It is always best to first check through patient testing, to determine whether or not chemotherapy would be beneficial.